Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $6.33.

Several equities analysts recently commented on INO shares. Jefferies Financial Group reiterated a “buy” rating and set a $8.00 price target (up from $3.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 6th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a research note on Thursday, November 12th. Piper Sandler reissued an “overweight” rating and issued a $6.00 price objective (down from $8.00) on shares of Inovio Pharmaceuticals in a research note on Wednesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a research report on Wednesday, November 11th. Finally, Zacks Research cut Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th.

View Our Latest Research Report on INO

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of large investors have recently bought and sold shares of INO. RA Capital Management L.P. purchased a new position in Inovio Pharmaceuticals during the 3rd quarter valued at $8,809,000. Marshall Wace LLP purchased a new stake in Inovio Pharmaceuticals in the third quarter worth $2,780,000. Eversept Partners LP purchased a new stake in Inovio Pharmaceuticals in the first quarter worth $1,802,000. Renaissance Technologies LLC increased its stake in Inovio Pharmaceuticals by 16.4% in the first quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock worth $1,120,000 after purchasing an additional 90,613 shares during the period. Finally, Green Alpha Advisors LLC lifted its position in shares of Inovio Pharmaceuticals by 68.8% during the third quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 46,802 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Up 2.9%

INO stock opened at $1.76 on Friday. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.72. The stock has a market capitalization of $193.92 million, a price-to-earnings ratio of -3.26 and a beta of 1.71. The firm’s fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $1.27.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last released its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $2.27 million. As a group, equities research analysts expect that Inovio Pharmaceuticals will post -0.97 EPS for the current year.

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Featured Stories

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.